Kiniksa Pharmaceuticals International Plc (KNSA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$78.95

From 52W high−4.55%

Volume1.01M

Market cap$6.03B

P/E (TTM)72.2x

P/S (TTM)7.2x

Div yield—

Key dataSep 18, 2026

Open

$78.95

From 52W high

−4.55%

Volume

1.01M

Market cap

$6.03B

ValuationView details →

P/E (Fwd)

48.7x

EV/EBITDA

49.2x

P/E (TTM)

72.2x

RSI (14)

53.6

MomentumView details →

1D Return

−2.63%

YTD Return

+89.64%

SummaryUpdated Jun 1, 2026

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biopharmaceutical company founded in 2015 and based in Hamilton, Bermuda. The company went public in May 2018 and focuses on developing and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Kiniksa has successfully transitioned from a development-stage company to a profitable commercial enterprise, primarily driven by the success of its flagship product ARCALYST for treating recurrent pericarditis, a rare inflammatory cardiovascular condition.

Ask drillr about Kiniksa Pharmaceuticals International Plc →

ValuationView details →

P/E (Fwd)

48.7x

P/E (TTM)

72.2x

EV/EBITDA

49.2x

EV/Sales

6.6x

P/S (TTM)

7.2x

P/B (TTM)

9.2x

ProfitabilityView details →

Gross Margin

54.49%

Net Margin

9.59%

EBITDA Margin

13.33%

ROE (TTM)

12.33%

ROA (TTM)

9.00%

Asset Turnover

0.98x

GrowthView details →

Revenue YoY

+58.85%

EPS YoY

+1683.33%

FCF YoY

+175.38%

Revenue CAGR 3Y

+45.45%

EPS CAGR 3Y

−32.83%

EBITDA YoY

+742.35%

MomentumView details →

1D Return

−2.63%

YTD Return

+89.64%

1Y Return

+120.85%

RSI (14)

53.6

vs 50D SMA

+5.26%

vs 200D SMA

+43.61%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.90x

Quick Ratio

3.49x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.30

EPS Surprise

0.17%

Beats (12Q)

8/12

Next Q EPS Est

$0.37

Avg Surprise (4Q)

−5.38%

Rev Surprise

7.56%

Financials snapshotView financials →

Revenue (TTM)

840.85M

Net Income (TTM)

80.66M

Op. CF (TTM)

185.23M

Next earningsOct 27, 2026 →

Latest newsMore news →

Kiniksa Pharmaceuticals International, plc reported Q2 2026 earnings of $0.3 per share, matching the Zacks Consensus Estimate and up from $0.23 per share a year ago.54d ago

Similar companies

科前生物688526.SH Liquidia CorporationLQDA Mirum Pharmaceuticals, Inc.MIRM 悦康药业688658.SH Terns Pharmaceuticals, Inc.TERN Travere Therapeutics, Inc.TVTX Find similar companies →

Latest newsMore news →

Kiniksa Pharmaceuticals International, plc reported Q2 2026 earnings of $0.3 per share, matching the Zacks Consensus Estimate and up from $0.23 per share a year ago.54d ago